Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas

Masahiro Mizoguchi1, Catherine L Nutt, Gayatry Mohapatra

  • 1Molecular Neuro-Oncology Laboratory, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital, Charlestown, MA 02129, USA.

Insights

Genetic alterations in phosphoinositide 3-kinase (PI3K) subunits, including PIK3CA, PIK3CD, and PIK3R1, can activate the PI3K-AKT pathway in glioblastomas. These PI3K gene mutations offer alternative mechanisms for pathway activation independent of PTEN loss.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Genetic alterations of phosphoinositide 3-kinase (PI3K) subunits are implicated in various cancers.
  • The PI3K-AKT signaling pathway is frequently activated in glioblastomas, often through PTEN loss.
  • Understanding PI3K subunit alterations is crucial for glioblastoma pathogenesis.

Purpose of the Study:

  • To investigate genetic alterations of class IA PI3K subunits in glioblastomas.
  • To determine if these alterations contribute to PI3K-AKT pathway deregulation.
  • To explore PI3K pathway activation mechanisms independent of PTEN mutations.

Main Methods:

  • Fluorescence in situ hybridization (FISH) to assess PIK3CA and PIK3CD copy numbers.
  • Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) to detect somatic mutations in PI3K subunits.
  • Analysis of AKT activation in relation to PTEN and PI3K mutations.

Main Results:

  • Frequent copy number increases observed for PIK3CA and PIK3CD.
  • A novel 9-bp deletion in PIK3R1 was identified, leading to a predicted truncated, hyperactive protein.
  • AKT activation was observed in cases with PIK3CA copy gain and PIK3R1 mutation, without PTEN mutation.

Conclusions:

  • Genetic alterations of class IA PI3K subunits (PIK3CA, PIK3CD, PIK3R1) can activate the PI3K-AKT pathway in glioblastoma.
  • These PI3K alterations represent an alternative mechanism for pathway activation, independent of PTEN loss.
  • These findings highlight the role of PI3K genetic changes in glioblastoma development.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...